Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05888857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Study acronym: TAYLOR
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 13, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 2023 to Sep 2025
    • Study completion date: Sep 2027 to Sep 2028
    v3
  2. Secondary endpoints: details revised at 1 of 13 entries
    • Study description revised
    • Study title shortened, about 6 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
Trial Details
NCT Number NCT05888857
Lead Sponsor Institut Bergonié
Collaborators: National Cancer Institute, France, AstraZeneca
Conditions
(from sponsor)		 Advanced Solid Tumor
Related terms Tertiary Lymphoid Structures
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov